Dose versus Time

P-32 is also an ideal radionuclide for brachytherapy bone cement due to its clinically relevant half-life (14.3 days), which is long enough to sustain its use from the time of manufacture to clinical implantation, yet short enough to deliver 94% of the total dose within 2 months.